Kessler L, Thivolet C, Penfornis A, Gouet D, Coffin C, Moret M
Diabetes Ther. 2024; 16(3):413-427.
PMID: 39688775
PMC: 11867997.
DOI: 10.1007/s13300-024-01673-9.
Tan Y, Suan E, Koh G, Suhairi S, Tyagi S
Arch Public Health. 2024; 82(1):231.
PMID: 39623499
PMC: 11610123.
DOI: 10.1186/s13690-024-01459-2.
Ishii H, Kamiya H, Takahashi Y, Morimoto Y, Yabe D
Diabetes Ther. 2024; 15(11):2381-2400.
PMID: 39347902
PMC: 11466927.
DOI: 10.1007/s13300-024-01645-z.
Badi S, Suliman S, Almahdi R, Aldomah M, Ahmed M, Elkheir H
J Prim Care Community Health. 2024; 15:21501319241279681.
PMID: 39279353
PMC: 11406634.
DOI: 10.1177/21501319241279681.
Cooper Z, Johnson L, Ali M, Patel S, Poongothai S, Mohan V
Diabet Med. 2024; 41(12):e15412.
PMID: 39039715
PMC: 11560630.
DOI: 10.1111/dme.15412.
Protocol for a prospective, multicenter, parallel-group, open-label randomized controlled trial comparing standard care with Closed lOoP In chiLdren and yOuth with Type 1 diabetes and high-risk glycemic control: the CO-PILOT trial.
Boucsein A, Zhou Y, Haszard J, Jefferies C, Wiltshire E, Styles S
J Diabetes Metab Disord. 2024; 23(1):1397-1407.
PMID: 38932805
PMC: 11196497.
DOI: 10.1007/s40200-024-01397-4.
Real-World Use of Oral Semaglutide in Adults with Type 2 Diabetes in the PIONEER REAL Netherlands Multicentre, Prospective, Observational Study.
van Houtum W, Schrombges P, Amadid H, van Bon A, Braae U, Hoogstraten C
Diabetes Ther. 2024; 15(8):1749-1768.
PMID: 38861137
PMC: 11263532.
DOI: 10.1007/s13300-024-01588-5.
Discordance between mean glucose and time in range in relation to HbA in individuals with type 1 diabetes: results from the GOLD and SILVER trials.
Sterner Isaksson S, Imberg H, Hirsch I, Schwarcz E, Hellman J, Wijkman M
Diabetologia. 2024; 67(8):1517-1526.
PMID: 38668761
PMC: 11343832.
DOI: 10.1007/s00125-024-06151-2.
Comparison between a tubeless, on-body automated insulin delivery system and a tubeless, on-body sensor-augmented pump in type 1 diabetes: a multicentre randomised controlled trial.
Kim J, Jin S, Kang E, Kwak S, Yang Y, Yoo J
Diabetologia. 2024; 67(7):1235-1244.
PMID: 38634887
DOI: 10.1007/s00125-024-06155-y.
Effects, Safety, and Treatment Experience of Advanced Hybrid Closed-Loop Systems in Clinical Practice Among Adults Living With Type 1 Diabetes.
Singh R, Imberg H, Seyed Ahmadi S, Hallstrom S, Jendle J, Tengmark B
J Diabetes Sci Technol. 2024; :19322968241242386.
PMID: 38629871
PMC: 11571990.
DOI: 10.1177/19322968241242386.
Role of dietary interventions on microvascular health in South-Asian Surinamese people with type 2 diabetes in the Netherlands: A randomized controlled trial.
van der Velden A, IJpelaar D, Chandie Shaw P, Pijl H, Vink H, van der Vlag J
Nutr Diabetes. 2024; 14(1):17.
PMID: 38600065
PMC: 11006941.
DOI: 10.1038/s41387-024-00275-5.
Differential Effects of Type 2 Diabetes Treatment Regimens on Diabetes Distress and Depressive Symptoms in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).
Gonzalez J, Bebu I, Krause-Steinrauf H, Hoogendoorn C, Crespo-Ramos G, Presley C
Diabetes Care. 2024; 47(4):610-619.
PMID: 38416773
PMC: 10973899.
DOI: 10.2337/dc23-2459.
The effect of carbohydrate intake on glycaemic control in individuals with type 1 diabetes: a randomised, open-label, crossover trial.
Sterner Isaksson S, Olafsdottir A, Ivarsson S, Imberg H, Toft E, Hallstrom S
Lancet Reg Health Eur. 2024; 37:100799.
PMID: 38362553
PMC: 10866914.
DOI: 10.1016/j.lanepe.2023.100799.
The Role of Ultra-Rapid-Acting Insulin Analogs in Diabetes: An Expert Consensus.
Giorgino F, Battelino T, Bergenstal R, Forst T, Green J, Mathieu C
J Diabetes Sci Technol. 2023; 19(2):452-469.
PMID: 37937585
PMC: 11874134.
DOI: 10.1177/19322968231204584.
Treatment Satisfaction and Quality of Life with Tirzepatide Versus Dulaglutide Among Japanese Patients with Type 2 Diabetes: Exploratory Evaluation of the SURPASS J-mono Trial.
Ishii H, Oura T, Takeuchi M
Diabetes Ther. 2023; 14(12):2173-2183.
PMID: 37843771
PMC: 10597937.
DOI: 10.1007/s13300-023-01485-3.
Development of a patient-reported outcome (PRO) measure to assess patient perceptions of simplicity and complexity of treatment for type 2 diabetes.
Stewart K, Matza L, Patel H, Boye K
J Patient Rep Outcomes. 2023; 7(1):89.
PMID: 37672123
PMC: 10482816.
DOI: 10.1186/s41687-023-00614-7.
Improved Glycaemic and Weight Management Are Associated with Better Quality of Life in People with Type 2 Diabetes Treated with Tirzepatide.
Boye K, Sapin H, Dong W, Williamson S, Lee C, Thieu V
Diabetes Ther. 2023; 14(11):1867-1887.
PMID: 37668888
PMC: 10570229.
DOI: 10.1007/s13300-023-01457-7.
Patient-Reported Outcomes in People with Type 2 Diabetes Receiving Tirzepatide in the SURPASS Clinical Trial Programme.
Boye K, Thieu V, Sapin H, Lee C, Lando L, Brown K
Diabetes Ther. 2023; 14(11):1833-1852.
PMID: 37526908
PMC: 10570242.
DOI: 10.1007/s13300-023-01451-z.
Treatment Satisfaction and Well-Being With Continuous Glucose Monitoring in People With Type 1 Diabetes: An Analysis Based on the GOLD Randomized Trial.
Pylov D, Polonsky W, Imberg H, Holmer H, Hellman J, Wijkman M
J Diabetes Sci Technol. 2023; 19(1):143-152.
PMID: 37501366
PMC: 11688678.
DOI: 10.1177/19322968231183974.
Development of a Patient-Reported Outcome (PRO) Measure to Assess Emotional Impact of Treatment for Type 2 Diabetes.
Boye K, Stewart K, Matza L
Diabetes Ther. 2023; 14(9):1451-1470.
PMID: 37351820
PMC: 10363102.
DOI: 10.1007/s13300-023-01426-0.
